Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00356265 · ClinicalTrials.gov registry record · NA
Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide
A NA study, sponsored by University of Michigan.
- Terminated
- Registry status
- NA
- Development phase
- 18
- Enrollment target
NCT00356265 is a NA study that was terminated before completion, run by University of Michigan. The registered enrollment target is 18 participants.
The verdict
NCT00356265, a NA study, was terminated before completion, sponsored by University of Michigan.
- TERMINATED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
Study Summary
The purpose of this study is to learn more about why most patients with early stages of kidney disease have high blood pressure. We know the body produces natural substances that cause blood vessels to open wider to carry more blood when needed. An example is during exercise. Other natural substances cause blood vessels to get smaller and slow down blood flow when needed. An example is when people are cold. The balance between these substances is important. People with kidney disease and high blood pressure do not have the normal balance of these substances. This study will include 3 groups of people, people with normal blood pressure, people with high blood pressure and people with kidney disease. * Subjects will have a screening physical examination, including an ECG and laboratory tests * Subjects with high blood pressure may not take their regular blood pressure medication for 3 weeks prior to the inpatient GCRC study * Subjects will be given intra-arterial medications that will cause changes in the blood vessels during the in-patient study. The study will then compare the responses of the three groups. A GFR test will be done to confirm the renal function of the group with chronic kidney disease. These studies will provide insight into the mechanisms of the pathogenesis of enhanced α1 vasoreactivity in subjects with progressive renal disease. This will lay the groundwork for new strategies in the treatment and prevention of vascular disease among the rapidly growing group of individuals with CKD.
Interventions
- DRUG Procedure: Regional phenylephrine arterial infusion
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2006-07 |
| Est. Completion | 2010-11 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00356265
The ClinicalTrials.gov registry entry for NCT00356265 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Michigan, which has 1,327 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Procedure: Regional phenylephrine arterial infusion is the first listed.
NCT00356265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00356265 about?
NCT00356265 is a clinical study titled "Alpha-Adrenoceptor Vascular Function In Chronic Kidney Disease Focus On The Role Of Endothelial Nitric Oxide". The purpose of this study is to learn more about why most patients with early stages of kidney disease have high blood pressure. We know the body produces natural substances that cause blood vessels to open wider to carry more blood when needed. An example is during exercise. Other natural substanc...
What is the current status of trial NCT00356265?
This trial is currently terminated. It is a NA study. The enrollment target is 18 participants. The study started on 2006-07. Estimated completion is 2010-11.
What interventions are being tested in trial NCT00356265?
The interventions under investigation include: Procedure: Regional phenylephrine arterial infusion (DRUG).
Who is sponsoring clinical trial NCT00356265?
This trial is sponsored by University of Michigan, which has 1,327 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.